Latest news with #ICVAX
Business Wire
19-06-2025
- Health
- Business Wire
PharmaJet ® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has entered into an agreement with Immuno Cure, a prominent developer of DNA vaccines. Under the terms of the agreement, Immuno Cure will use PharmaJet's Tropis ID system in a human clinical trial to deliver their novel HIV-1 therapeutic DNA Vaccine (ICVAX). The agreement was executed on June 16, 2025, during a signing ceremony at the 2025 BIO International Convention in Boston, Massachusetts. The study follows the successful first-in-human ICVAX Phase 1 clinical trial that showed exceptional safety and promising immunogenicity profiles. 3 The vaccine represents a significant step towards achieving virological control by ICVAX without antiretroviral therapy and ultimately becoming a functional cure of human immunodeficiency virus (HIV)/AIDS. Immuno Cure is investigating the potential for the Tropis ID system to improve the DNA vaccine performance and patient's clinical experience. Intradermal delivery is expected to help elicit long-lived and cross-reactive immune responses. The Tropis system easily leverages the rich network of dendritic cells, macrophages and T cells in the dermal layer and can provide a more potent and broader immunogenic response than vaccinating into the muscle. 1 Tropis is commercially scaled, has been used for over 12 million injections, and is the first and only needle-free ID delivery technology to achieve World Health Organization (WHO) prequalification. Dr. Xia Jin MD PhD, CEO of Immuno Cure, said, 'At Immuno Cure, our mission is to advance transformative therapies for infectious diseases and cancer. We are excited to partner with PharmaJet and leverage their Tropis Needle-free Injection System on our HIV therapeutic DNA vaccine program. We value innovative approaches that could enhance patient experience and vaccine performance.' 'This agreement adds to our portfolio of global development partnerships with innovative oncology and infectious disease developers. Our partners are joining our call to challenge antiquated IM administration methods in favor of ID delivery based on the growing body of evidence 4 demonstrating improved immune responses and safety profiles,' said Dan Mallon, Senior Vice President Corporate Development, PharmaJet. 'PharmaJet's needle-free technology is safe and well-tolerated and has shown to enable immune responses that are robust and durable.' 1 Kupper, T. S. & Fuhlbrigge, R. C. (2004). Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 4, 211-222. 2 Teixeira, L. et al. (2020). A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors. Clin Cancer Res 26, 588-597 3 I mmuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine, Nov. 12, 2024 4 Ledesma-Feliciano C, et al (2023). Improved DNA Vaccine Delivery with Needle-free Injection Systems. Vaccines. 11(2):280 Expand About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis ® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About Immuno Cure Immuno Cure is a clinical-stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-Enhanced DNA Vaccine, Anti-Δ42PD1 Antibody and Vaccine Delivery Platform. To learn more about Immuno Cure, please visit:
Yahoo
19-06-2025
- Health
- Yahoo
Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans
HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, delivered via PharmaJet's innovative Tropis® needle-free injection system in a clinical study. On June 16, 2025, Immuno Cure and PharmaJet held a material transfer agreement ("MTA") signing ceremony at the BIO 2025 International Convention in Boston, USA to commemorate such collaboration. HIV/AIDS remains a critical global health challenge today, despite advances in treatment and prevention. As of 2023, over 39 million people were living with HIV, and more than 40 million deaths have occurred since the start of the epidemic in 1981. Current antiretroviral therapy ("ART") is highly effective in suppressing the virus in HIV-1 infected individuals, but it does not provide a cure. This underscores the necessity for an effective immunotherapy that can enhance the host immune response to establish a state of ART-free virological control, or a functional cure. ICVAX employs Immuno Cure's patented PD-1-Enhanced DNA Vaccine technology, which aims to achieve sustained, immune-mediated HIV-1 virological control without the need of ART. Following the successful first-in-human ICVAX Phase I clinical trial that showed exceptional safety and immunogenicity profiles, this new clinical study will explore the use of the WHO prequalified PharmaJet Tropis device for the administration of ICVAX, which allows precise intradermal delivery through its advanced needle-free technology. Tropis' global regulatory clearances and manufacturing scale reduce development risk and may improve the DNA vaccine performance and patient's clinical experience. This study will be conducted at Prince of Wales Hospital in Hong Kong SAR, led by Professor Grace LUI, Head of the Division of Infectious Diseases at the Faculty of Medicine, the Chinese University of Hong Kong ("CUHK"). This study is a collaborative effort among Immuno Cure, CUHK, and the AIDS Institute of the University of Hong Kong, and is partially supported by the funding from the Public Sector Trial Scheme of the Innovation and Technology Commission of the HKSAR Government. Professor Zhiwei CHEN, Director of the AIDS Institute of the University of Hong Kong, serves as the Project Coordinator for this funding. Dr. Xia JIN MD PhD, CEO of Immuno Cure, said "We are thrilled to partner with PharmaJet on this innovative delivery approach to HIV treatment. This collaboration not only advances needle-free vaccination solutions but also accelerates the global commercialization potential for ICVAX and the vaccine's ability to transform HIV management." Mr. Dan MALLON, Senior Vice President of Corporate Development of PharmaJet, added "We are excited to support Immuno Cure's novel HIV-1 therapeutic vaccine program with PharmaJet's patented needle-free injection technology. PharmaJet is one of the leaders in nucleic acid-based vaccine and therapeutic delivery and we are encouraged by the potential for the Tropis intradermal delivery system to make a substantial impact for HIV patients. This partnership reflects our shared commitment to advancing innovative, patient-friendly technologies that address unmet medical needs globally." Immuno Cure and PharmaJet are committed to pioneering new frontiers in vaccine delivery and enhancing patient experiences through cutting-edge technologies. About Immuno Cure Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine, Anti-Δ42PD1 Antibody; and Vaccine Delivery platforms. To learn more about Immuno Cure, please visit: About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. To learn more about PharmaJet, please visit: Media Contact:Immuno Cure Ms. Carol CHUNG Email: carolchung@ Immuno Cure Dr. Anthony CHEUNG Email: anthonycheung@ PharmaJet Ms. Nancy LILLIE Email: PharmaJet Mr. Dan MALLON Email: View original content to download multimedia: SOURCE IMMUNO CURE HOLDING (HK) LIMITED Sign in to access your portfolio
The Sun
17-06-2025
- Business
- The Sun
HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
HONG KONG SAR - Media OutReach Newswire - 17 June 2025 - Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) - to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub. The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms. During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities: • Immuno Cure, partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. • HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth. Mr. Albert Wong, CEO of HKSTP, said: 'We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation.' Ahead of BIO 2025, the delegation participated in the '2025 Biomedical Pitch Competition', co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth. HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as 'Edison of Medicine'), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader. Appendix: List of Park Companies Participating in BIO 2025: 1. Allegrow Biotech Limited 2. ARBELE Limited 3. Beth Bioinformatics Co., Limited 4. Centre for Translational Stem Cell Biology 5. The Centre for Virology, Vaccinology, and Therapeutics 6. DECODE CURE Limited 7. GenEditBio Limited 8. Great Bay Bio 9. Hong Kong Universal Biologicals Company Limited 10. Immuno Cure Holding (HK) Limited 11. The Institute for Innovation, Translation and Policy Research (ITPR) 12. LEE'S PHARMACEUTICAL (HK) LIMITED 13. Serilink Biotechnology Company Limited 14. Xiaomo Biotech Limited 15. XUXIN (HongKong) Biotechnology Co., Limited 16. Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited Hashtag: #HKSTP
Arabian Post
17-06-2025
- Business
- Arabian Post
HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
Seizing Global Business and Investment Opportunities for Sustainable Growth HONG KONG SAR – Media OutReach Newswire – 17 June 2025 – Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) – to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub. In collaboration with InvestHK, HKSTP joined forces with the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) for the first time to form a delegation and led 16 prominent life and health technology companies to showcase at BIO 2025 held in Boston, USA. The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms. ADVERTISEMENT During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities: Immuno Cure , partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. , partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth. Mr. Albert Wong, CEO of HKSTP, said: 'We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation.' Ahead of BIO 2025, the delegation participated in the '2025 Biomedical Pitch Competition', co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth. HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as 'Edison of Medicine'), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader. Appendix: List of Park Companies Participating in BIO 2025: ADVERTISEMENT Allegrow Biotech Limited ARBELE Limited Beth Bioinformatics Co., Limited Centre for Translational Stem Cell Biology The Centre for Virology, Vaccinology, and Therapeutics DECODE CURE Limited GenEditBio Limited Great Bay Bio Hong Kong Universal Biologicals Company Limited Immuno Cure Holding (HK) Limited The Institute for Innovation, Translation and Policy Research (ITPR) LEE'S PHARMACEUTICAL (HK) LIMITED Serilink Biotechnology Company Limited Xiaomo Biotech Limited XUXIN (HongKong) Biotechnology Co., Limited Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited Hashtag: #HKSTP The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in stablishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at
Yahoo
17-06-2025
- Business
- Yahoo
HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
Hong Kong SAR--(Newsfile Corp. - June 17, 2025) - Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties--the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) - to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub. In collaboration with InvestHK, HKSTP joined forces with the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) for the first time to form a delegation and led 16 prominent life and health technology companies to showcase at BIO 2025 held in Boston, USA. To view an enhanced version of this graphic, please visit: The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms. During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities: Immuno Cure, partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth. Mr. Albert Wong, CEO of HKSTP, said: "We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation." Ahead of BIO 2025, the delegation participated in the "2025 Biomedical Pitch Competition", co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies--ARBELE, GenEditBio, and Cogsmart--excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth. HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as "Edison of Medicine"), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader. Appendix: List of Park Companies Participating in BIO 2025: Allegrow Biotech Limited ARBELE Limited Beth Bioinformatics Co., Limited Centre for Translational Stem Cell Biology The Centre for Virology, Vaccinology, and Therapeutics DECODE CURE Limited GenEditBio Limited Great Bay Bio Hong Kong Universal Biologicals Company Limited Immuno Cure Holding (HK) Limited The Institute for Innovation, Translation and Policy Research (ITPR) LEE'S PHARMACEUTICAL (HK) LIMITED Serilink Biotechnology Company Limited Xiaomo Biotech Limited XUXIN (HongKong) Biotechnology Co., Limited Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited Hashtag: #HKSTP The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in stablishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at Media Contact: Angela LauPhone: +852 2629 6633Email: To view the source version of this press release, please visit Sign in to access your portfolio
